---

**From:** Janice Barnett <caitlynfrench@example.net>  
**To:** Mary Rogers <herringedwin@example.net>  
**Subject:** RE: Risk Assessment for Project Helios  

Hi Mary,

Thank you for sending over the initial findings for Project Helios. I've reviewed the risk assessment report, and I have a few observations and suggestions.

1. **Data Integrity:** Given the sensitive nature of the compounds we are dealing with, it's crucial to ensure data integrity at every stage of the trial. I recommend a secondary review process for data entry points to mitigate any potential discrepancies.

2. **Regulatory Compliance:** Considering the recent changes in FDA regulations, it might be worthwhile to have a compliance audit before we proceed to the next phase. This will help us align with the updated guidelines and avoid any compliance-related setbacks.

3. **Stakeholder Communication:** Let's set up a meeting with the key stakeholders next week to discuss these points in detail. How does Wednesday at 10 AM sound? We can meet in Conference Room B on the 5th floor.

Please let me know if this timing works for you, or feel free to suggest another slot. You can reach me at my direct line, 555-0123, if you need to discuss anything urgently.

Looking forward to your thoughts.

Best,  
Janice Barnett  
Loss Adjuster, Chartered  
Merck & Co., Inc.

---

**From:** Mary Rogers <herringedwin@example.net>  
**To:** Janice Barnett <caitlynfrench@example.net>  
**Subject:** Risk Assessment for Project Helios  

Hi Janice,

I hope this email finds you well. I’ve attached the initial findings of our risk assessment for Project Helios. Please review the document and let me know your thoughts.

Our primary focus has been on potential risks associated with the new compound development and its market entry. We've identified some areas that might need further scrutiny, especially concerning supply chain vulnerabilities and market volatility.

I’m particularly interested in your perspective on the financial implications of these risks, as your expertise in adjusting for potential losses will be invaluable.

Looking forward to your feedback.

Best regards,  
Mary Rogers  
Research Officer  
Merck & Co., Inc.